Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+
With the approval of ABRYSVO® for adults aged 18+, there is now a way to help protect against RSV in a population that previously did not have vaccination options. Pfizer Canada ULC announced today that Health Canada has approved a new indication for ABRYSVO®, the respiratory syncytial virus (RSV) stabilized prefusion F subunit bivalent vaccine, […]